Revenue increased to 34,324 million yen (YoY 105.1%). Operating income was 2,455 million yen, and net income attributable to owners of parent was 1,198 million yen. A goodwill impairment loss of 435 million yen was recorded as an extraordinary loss. For the fiscal year ending August 2027, full-year forecasts are revenue of 17,610 million yen, operating income of 1,272 million yen, and net income of 815 million yen (year-on-year changes are as stated).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2927","jir_company_name":"AFC-HD AMS Life Science Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-15","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/2927-20261015-01.pdf","jir_short_summary":"Revenue increased to 34,324 million yen (YoY 105.1%). Operating income was 2,455 million yen, and net income attributable to owners of parent was 1,198 million yen. A goodwill impairment loss of 435 million yen was recorded as an extraordinary loss. For the fiscal year ending August 2027, full-year forecasts are revenue of 17,610 million yen, operating income of 1,272 million yen, and net income of 815 million yen (year-on-year changes are as stated).","jir_summary":"### Overview of Results\nFor the fiscal year ended August 2026, the Company achieved increased revenue of 34,324 million yen (YoY 105.1%). Operating income was 2,455 million yen and ordinary income was 2,390 million yen. Net income amounted to 1,198 million yen due to recording a goodwill impairment loss of 435 million yen as an extraordinary loss. By segment, Healthcare and Pharmaceuticals were the main drivers: Healthcare recorded revenue of 20,034 million yen and Pharmaceuticals 2,569 million yen, with Department Stores, Foodservice, Real Estate & Construction, and Others showing their respective trends. Total assets were 49,046 million yen and net assets were 16,435 million yen.\n\n### Outlook and Capital Allocation\nFor the fiscal year ending August 2027, full-year forecasts are revenue of 17,610 million yen, operating income of 1,272 million yen, ordinary income of 1,215 million yen, and net income attributable to owners of parent of 815 million yen. The Company expects main businesses to remain steady and plans to continue promoting new businesses such as the integration of Rabbit Express into the group, as well as initiatives in the real estate, construction, and tourism sectors. Financial position remains on a stable footing with net assets of 16,435 million yen and an equity ratio of 33.0%.","jir_financial_highlights":"Revenue: 34,324 million yen (YoY 105.1%)\nOperating Income: 2,455 million yen (YoY 101.9%)\nOrdinary Income: 2,390 million yen (YoY 97.8%)\nNet Income Attributable to Owners of Parent: 1,198 million yen (YoY 82.8%)\nEquity Ratio: 33.0% (Prior term 30.9%)","jir_category":"","jir_hashtags":"#AFC-HD_AMS_Life_Science, #Earnings, #SegmentRevenue, #GoodwillImpairment, #MidTermManagementPlan","jir_key_figures":"Revenue: 34,324 million yen (YoY 105.1%)\nOperating Income: 2,455 million yen (YoY 101.9%)\nNet Income Attributable to Owners of Parent: 1,198 million yen (YoY 82.8%)","jir_meta_title":"AFC-HD AMS Life Science Co., Ltd. - Financial Summary Overview | Fiscal Year Ended August 2026","jir_meta_description":"Key points from AFC-HD AMS Life Science Co., Ltd.'s financial summary for the fiscal year ended August 2026: revenue 34,324 million yen, operating income 2,455 million yen, net income 1,198 million yen. Includes impact of goodwill impairment and full-year outlook for 2027.","jir_og_title":"AFC-HD AMS Life Science Co., Ltd. - Financial Summary FY Aug 2026","jir_og_description":"Financial summary for AFC-HD AMS Life Science Co., Ltd. for the fiscal year ended August 2026: revenue 34,324 million yen, operating income 2,455 million yen, net income 1,198 million yen. Outlook for the coming year is also highlighted.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Aug 2025\\\",\\\"Fiscal Year Aug 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[32655,34324]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Aug 2025\\\",\\\"Fiscal Year Aug 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[2409,2455]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"net_income_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Aug 2025\\\",\\\"Fiscal Year Aug 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[1198,1198]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"net_assets_ratio\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Equity Ratio Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Aug 2025\\\",\\\"Fiscal Year Aug 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Equity Ratio\\\",\\\"data\\\":[30.9,33.0]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Revenue by Segment (External Customers)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Healthcare\\\",\\\"Pharmaceuticals\\\",\\\"Department Stores\\\",\\\"Foodservice\\\",\\\"Real Estate & Construction\\\",\\\"Others\\\"],\\\"datasets\\\":[{\\\"data\\\":[20034,2569,4568,2549,2728,1875]}]},\\\"options\\\":{}}\"}]","ir_related_company":58627,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-131940","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n